Edition:
United States

Claris Lifesciences Ltd (CLAI.BO)

CLAI.BO on Bombay Stock Exchange

360.25INR
1:23am EDT
Change (% chg)

Rs-2.50 (-0.69%)
Prev Close
Rs362.75
Open
Rs361.10
Day's High
Rs361.95
Day's Low
Rs360.00
Volume
7,568
Avg. Vol
118,094
52-wk High
Rs430.10
52-wk Low
Rs217.30

CLAI.BO

Chart for CLAI.BO

About

Claris Lifesciences Limited is a holding company. The Company is engaged in manufacturing of drugs and pharmaceutical products. The Company's geographical segments are India and Outside India. The Company's subsidiary, Claris Injectables Limited, is engaged in specialty Injectables business. The Company manufactures and markets... (more)

Overall

Beta: 0.97
Market Cap(Mil.): Rs20,029.10
Shares Outstanding(Mil.): 54.57
Dividend: 2.00
Yield (%): 0.54

Financials

  CLAI.BO Industry Sector
P/E (TTM): -- 31.64 32.84
EPS (TTM): -7.85 -- --
ROI: -- 15.30 14.86
ROE: -- 16.32 16.11

BRIEF-India's Claris Lifesciences June-qtr consol profit down 13 pct

* June quarter consol profit 192.1 million rupees versus profit of 220 million rupees last year

Aug 11 2017

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

Jul 20 2017

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON, July 20 Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

Jul 20 2017

BRIEF-Claris Lifesciences underwent a successful USFDA Pharmacovigilance (PV) audit

* Says underwent a successful USFDA Pharmacovigilance (PV) audit from Monday 29th may to Wednesday 31st May with no observation

Jun 01 2017

BRIEF-Claris Lifesciences approves sale of shares of Otsuka Pharmaceutical India for $20 mln

* Says approved sale of shares of Otsuka Pharmaceutical India to Otsuka Pharmaceutical Factory for $20 million Source text for Eikon: Further company coverage:

May 08 2017

BRIEF-Claris Lifesciences gets members' nod for sale, transfer of injectable business

* Gets members' nod for sale and transfer of injectable business of co by way of sale of subsidiary companies Source text: http://bit.ly/2kD0uPT Further company coverage:

Feb 20 2017

Earnings vs. Estimates